Los bárbaros están de nuevo a las puertas. Los bárbaros son las empresas de capital riesgo y las puertas, las fronteras españolas. Estos inversores —bautizados así en el libro Barbarians at the gates, que cuenta la batalla por hacerse con RJR Nabisco— desembolsaron 3.465 millones en 2014 en 580 operaciones, un 45% más que un año antes. La mayor parte de ese dinero pertenece a fondos extranjeros y los sectores más activos son consumo, industria, turismo y salud.
Portobello, una de las firmas de private equity con más experiencia en España, tiene encima de la mesa una oferta para vender de una sola vez todas las empresas en las que ha invertido en los últimos nueve años. Según aseguran fuentes del sector, el fondo estadounidense HarbourVest se ha interesado por quedarse con un portfolio que incluye compañías como Angulas Aguinaga y Multiasistencia.
Los Consejos de Administración de la empresa de capital riesgo Dinamia y de su gestora, N+1, han aprobado y suscrito conjuntamente el proyecto común de fusión de ambas compañías. La ecuación de canje supone atribuir a los accionistas de Dinamia el 43% de la compañía fusionada y a los de N+1 el 57%.
Logos de las dos compañías que se han fusionado / Elaboración propia
In biotech, young companies have been raising money from public and private investors alike at an astounding rate. But all the rain isn’t letting a thousand flowers bloom.
In other words, there’s more money going into new biopharma companies, but the cash is not being spread widely. That’s according to a new survey released today by the Biotechnology Industry Organization, biotech’s top trade group.
Venture capital investing in biotech has long been hard to disaggregate: how much goes to “early stage” vs “late stage”, how much goes to CNS vs oncology, discovery vs Phase 3, etc…
Today BIO’s David Thomas and Chad Wessel have put some much-needed light onto the biotech investor trends over the past decade with a newly released report (here).
Analyzing the digital health/health IT investment activity of 12 of the top venture firms as identified by our tech unicorn VC analysis and 8 other top tier firms based on our Investor Mosaic models, we analyzed where the smart money is going in digital health / health IT. Specifically, the VC firms whose digital health investments are analyzed include:
Silicon Valley Bank’s annual healthcare M&A report, Trends in Healthcare Investments and Exits, examines the merger and acquisition and IPO activity of private, venture-backed biopharma and medical device companies.
Funding to education technology companies showed no signs of a slowdown in 2014. According to CB Insights data, Ed Tech companies ranging from K-12 APIs to MOOCs to student-teacher messaging apps raked in $1.87B across 350 deals – a new record for both deals & dollars in the space. This data first appeared in a New York Times article detailing Silicon Valley’s rising interest in disrupting education.
Germany’s tech scene saw increased funding figures for its tech hub, Berlin, increased foreign VC participation, and one of its most notable investors go public in 2014. With this increased buzz and VC dollars, 15 VC-backed tech companies raised $20M+ rounds of financing this past year. The largest was Delivery Hero, the online food ordering site which closed three separate rounds of financing totaling over $450M, including a $350M Series G which valued the company at $1B.
From smart thermometers to connected kitchen devices to vehicle WiFi hotspots, the Internet of Things ecosystem is expanding rapidly with a host of new applications and technologies. Using CB Insights interactive rankings feature, we compiled a list of the most active venture capital and corporate investors in the IoT space in 2014.
Intel Capital tops the list based on unique company deals in 2014, followed by Sequoia Capital and True Ventures, which has made the IoT vertical a key focus area of its portfolio.
